Drug profile · INN
spesolimab
SPEVIGO
spesolimab (SPEVIGO) is a il36 receptor antagonist.
EMA: approved Antineoplastic and immunomodulating agents (L04) L04AC22
Patents linked 0
Pipeline programs 9
News articles 0
Drug details — spesolimab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 9
- Data quality
- 0.83
Quick answer
spesolimab (SPEVIGO) is a il36 receptor antagonist.
Key facts
INN spesolimab
Brand SPEVIGO
Mechanism IL36 receptor antagonist
Target IL36 receptor
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AC22
Mechanism of action
IL36 receptor antagonist
Primary target: IL36 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is spesolimab?
spesolimab (SPEVIGO) is a il36 receptor antagonist.
What is the brand name for spesolimab?
SPEVIGO is a marketed brand name for spesolimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.